Therapeutic options in prevention and treatment of aspartoacylase gene mutation resulting abnormalities in Canavan disease

Keyphrases

• Therapeutic Potential 100%
• Gene mutation 100%
• Canavan Disease 100%
• Aspartoacylase 100%
• Glutamate 20%
• Interleukin-1β 20%
• Cell Death 20%
• Osteoporosis 20%
• Putative Drug Targets 20%
• Pathophysiological Processes 20%
• Autosomal Recessive 20%
• Serine Protease Inhibitor 20%
• Enzyme Deficiency 20%
• Aspartate 20%
• High-level Expression 20%
• GABAA Receptor (GABAAR) 20%
• Pharmacological Manipulation 20%
• Spongy Degeneration 20%
• Inhibitor-2 20%
• GABRA6 20%
• Glutamate Transporter 1 (GLT-1) 20%
• EAAT4 20%
• Inducing Agents 20%
• Abnormal Gene Expression 20%
• Caspase-11 20%
• Metabolic Level 20%
• Genomic Abnormalities 20%

Neuroscience

• Gene Mutation 100%
• Aspartoacylase 100%
• Canavan Disease 100%
• Gene Expression 20%
• Glutamic Acid 20%
• Gamma-Aminobutyric Acid 20%
• Aspartic Acid 20%
• Cell Death 20%
• Autosomal Recessive Disorder 20%
• Interleukin 1 20%
• Serine Protease 20%
• Glutamate Transporter 20%
• GABRA6 20%
• GABA Receptor 20%
• Caspase 11 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Aspartoacylase 100%
• Canavan Disease 100%
• Glutamic Acid 20%
• 4 Aminobutyric Acid 20%
• Interleukin 1 20%
• Aspartic Acid 20%
• Serine Proteinase Inhibitor 20%
• Enzyme Deficiency 20%
• Autosomal Recessive Disorder 20%
• Glutamate Transporter 20%
• 4 Aminobutyric Acid Receptor 20%
• Caspase 11 20%